Illumina

Youtube Subscribe

Open: 212.1 Close: 205.87 Change: -6.23

You don't have time to read all about Illumina Company Inc. An AI summarizes all the information for you.

How much time have you spent trying to decide whether investing in Illumina? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Illumina are: Illumina, Icahn, …

Concept Map

Semantic Network

Stock Summary

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. The company offers sequencing and array-based instruments and consumables, which include reagents, flow.

Today's Summary

Francis deSouza steps down as CEO of Illumina amid a bruising battle with regulators to acquire Grail, the cancer blood test startup. Activist investor Carl Icahn launched a proxy fight with the company over the $7.1 billion acquisition of cancer test maker Grail.

Today's News

Francis deSouza steps down as CEO of Illumina amid a bruising battle with regulators to acquire Grail, the cancer blood test startup. Activist investor Carl Icahn launched a proxy fight with the company over the $7.1 billion acquisition of cancer test maker Grail. Icahn has accused Illumina executive management and board of poor oversight. Francis deSouzas abrupt departure from Illumina suggests a major shift at the company. Analysts and customers wonder where his successor will steer the company next. Illumina, Inc. manufactures, manufactures, analyzes the analysis of genetic variation and biological function. During that time, Illumina saw a 53% drop in value. Illumina sells a number of high-through-put DNA sequencing systems, also known as DNA sequencers, based on technology developed by Solexa. Illumina already held 70% of the market for genome-sequencing machines in January 2014. In late 2015, Illumina spun off the company Grail focused on blood testing for cancer tumors. Illumina uses next-generation sequencing, which is far faster and more efficient than traditional Sanger sequencing. Illumina sequencers perform short-read sequencing and are image based, utilizing Illumina dye sequencing. Illumina CEO Francis deSouza resigns amid pressure from activist investor Carl Icahn. CEO resigns as company continues to look for new CEO. Illumina CEO steps down amid proxy battle with activist investor Carl Icahn. Shares rise as CEO steps. Nasdaq acquires Adenza in $10.5 billion deal. Illumina CEO Francis deSouza resigns after proxy battle with activist investor Carl Icahn. Activist investor Icahn wants former Chief Executive Jay Flatley to return to the gene-sequencing test maker. Illumina CEO Francis deSouza resigns after proxy battle with carlahn. Illumina is improving human health by unlocking the power of the genome. Analyst Price Forecast Suggests 21.53% upside. First Republic Investment Management increased its position in Illumina by 11.3% in the fourth quarter. Analysts predict that Illumina will continue growing throughout 2023. Illumina, Inc. (ILMN) up 3.73% in premarket trading. Illumina CEO Francis deSouza resigns amid pressure from activist investor Carl Icahn. Icahn survived a proxy challenge from the San Diego genetic sequencing pioneer. Illumina CEO Francis deSouza has resigned, just weeks after the DNA sequencing company endured a proxy fight with activist investor Carl Icahn. Icahn in a tweet said he is happy with the recent changes at Illumina. Illumina CEO steps down amid ongoing battle over deal for cancer test developer Grail. CEO Francis deSouza resigned from the gene sequencing company as of Sunday. Illumina CEO Francis deSouza steps down on Sunday, marking a victory for activist investor Carl Icahn. Icahn in a tweet said he is happy with the recent changes at Illumina and considers them a very positive occurrence Shares rose 2.2% to $204.98 in premarket trading on Monday. Illumina CEO Francis deSouza has resigned from both his position and his seat on the board. Activist investor Carl C. Icahn led a proxy campaign to oust him that was led by Icahn. Icahn: All these changes are important steps for Illumina in particular and activism in general Illuminas stock price has shrunk to the point where the company has lost some $50 billion in market capitalization. Icahn says Illumina has drained itself of resources through its nearly three-year effort to acquire cancer test developer Grail.

Stock Profile

"Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. Further, it provides whole-genome sequencing, genotyping, NIPT, and product support services; and Galleri, a multi-cancer early detection test. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Further, it markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California."

Keywords

Are looking for the most relevant information about Illumina? Investor spend a lot of time searching for information to make investment decisions in Illumina. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Illumina are: Illumina, Icahn, CEO, Francis, deSouza, investor, Carl, and the most common words in the summary are: illumina, stock, best, ceo, news, market, desouza, . One of the sentences in the summary was: Francis deSouza steps down as CEO of Illumina amid a bruising battle with regulators to acquire Grail, the cancer blood test startup. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #illumina #stock #best #ceo #news #market #desouza.

Read more →

Youtube Subscribe

---